Clinical research

SURPASS-CVOT: Cardiovascular outcomes with tirzepatide

Released: · Last reviewed: · By Dr. Parmis

Phase 3 cardiovascular outcomes trial. 13,299 randomised, over Approximately 4.5 years. Sponsor: Eli Lilly and Company.

SURPASS-CVOT (NCT04255433) tested at Maximum tolerated against dulaglutide in .Non-inferior to dulaglutide for MACE. This is not a demonstration of superiority over placebo Unverified — no source on file: the source is a citable record we could not authoritatively link, which we have not independently re-extracted from the full paper in this session.

Study design

DesignPhase 3 cardiovascular outcomes trial
PopulationNot stated
Sample size13,299 randomised
InterventionNot stated (Maximum tolerated)
ComparatorDulaglutide
DurationApproximately 4.5 years
Primary endpointMajor adverse cardiovascular events
SponsorEli Lilly and Company

Results

Non-inferior to dulaglutide for MACE. This is not a demonstration of superiority over placebo

Adverse events & discontinuations

Not extracted from the source in this session.

Limitations

An active-comparator non-inferiority design. Non-inferiority to another GLP-1 is a different claim from cardiovascular benefit versus placebo, and the two are frequently conflated.

Practical interpretation

This is one trial, reported by Eli Lilly and Company, read directly against the registry and publication linked below — GLP Ranked has not re-run the statistics or obtained the patient-level data. Results describe group averages under trial conditions and may not describe any individual's outcome, including with a compounded, non-FDA-approved version of a similar active ingredient. Always check the primary source before citing a specific number.

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.

Sources

  1. SURPASS-CVOT, 2024. NCT04255433 (source URL not published — treat as unverified) — Peer-reviewed publication
  2. SURPASS-CVOT — ClinicalTrials.gov record NCT04255433 — Trial registry record
  3. PubMed search: SURPASS-CVOT — Literature database search, checked November 21, 2026
  4. DailyMed (NLM): Zepbound (tirzepatide) prescribing information — FDA-approved label database, checked November 21, 2026
  5. DailyMed (NLM): Mounjaro (tirzepatide) prescribing information — FDA-approved label database, checked November 21, 2026

Cite this page

GLP Ranked. "SURPASS-CVOT: Cardiovascular outcomes with tirzepatide." https://glpranked.com/research/tirzepatide-cardiovascular-outcomes/

GLP Ranked. "SURPASS-CVOT: Cardiovascular outcomes with tirzepatide." https://glpranked.com/research/tirzepatide-cardiovascular-outcomes/